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1. INTRODUCTION 
Drug delivery refers to approaches for transporting drugs in the body, with the 
objective to achieve site-targeting in the organism. Drug delivery technologies modify 
drug release profile, absorption, distribution and elimination, giving rise to an 
improvement in drug efficacy and safety over the free form of the bioactive agent. An 
ideally controlled release of a drug means that the liberation of the pharmacological 
compound is produced in a constant and prolonged way, not exceeding the toxicity 
levels but surpassing the minimum effective level. 
In order to achieve a controlled release of drugs, the use of nanocarriers in drug 
delivery has been proposed[1]. These systems can provide many advantages, such as the 
improvement of drug solubility and stability in the bloodstream, the reduction of 
drug toxicity and its associated side effects thanks to the reduction of the doses, the 
increasing of immune responses in vaccine formulations, the use of sensitive 
nanocarriers that only release the drug when external stimuli is applied,  and the 
potential to deliver drugs in a targetable manner, delivering sufficiently high local 
amounts to avoid the development of resistant parasite strains.  
One of the most important features of nanocarriers is their size, since it controls the 
dwell time in the bloodstream, as well as their internalization within the cell and 
bioavailability of drug-containing nanoparticles[2]. Nanocarriers with sizes ranging from 
10 to 100 nm are optimal for the application in drug delivery. 
Among the different types of nanocarriers assayed as drug delivery systems, polymeric 
micelles have been successful for biomedical applications[3],[4],[5]. Polymeric micelles 
are aqueous dispersions of amphiphilic block copolymers that form particles of 
nanometric size (10-1000 nm). This kind of structures presents features of both 
nanoparticles and hydrogels, i.e. the ability to interact with biological systems due to its 
small size, as well as to hold large amounts of water. Polymeric micelles can be 
stabilized by crosslinking providing Cross-Linked Polymeric Micelles (CLMPs)[6],[7], 
in which the preformed micellar assemblies are blocked via covalent bonding. 
CLPMs must be composed of biodegradable compounds, allowing a stable and 
prolonged liberation of the drug as the carrier degrades. Due to the amphiphilic nature 
of the constituent polymer, which results in the formation of a lipophilic core and a 
hydrophilic shell, CLPMs can encapsulate both liposoluble and hydrosoluble drugs 
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within their polymeric matrix. Drugs can be captured by non-covalent interactions 
(ionic interactions, hydrogen bonding, hydrophobic interactions, etc.) or covalently 
incorporated within the polymeric structure. 
Moreover, drug liberation can also be controlled by using CLPMs that respond to 
external stimuli[8]. This kind of materials is able to modify its structural composition 
or conformation when a certain physical or chemical stimuli is produced, promoting 
the controlled liberation of the active species previously encapsulated in the nanocarrier. 
Thermosensitive CLPMs are one of the most studied systems, and they are composed 
of polymeric materials that contain thermosensitive units in their structure[9]. These 
stimuli-responsive materials modify their conformation when the temperature varies, 
presenting an expanded conformation at low temperatures, which allows an easy entry 
and exit of the encapsulated drug, whereas at higher temperatures the nanocarrier 
contracts, holding the drug within the polymeric matrix and giving rise to a slower and 
more controlled drug release. 
Pluronic® F-127 is an amphiphilic block copolymer widely used to form 
nanocarriers for drug delivery, among many other biomedical applications[10],[11]. It is 
composed by two polyethylene oxide (PEO) units separated by a central polypropylene 
oxide (PPO) unit. Moreover, Pluronic© F127 presents thermoresponsive properties. 
This compound is soluble in water at low temperatures and is able to self-arrange in 
water above a certain temperature (Critical Micelle Temperature) and concentration 
(Critical Micelle Concentration), forming micelles consisting of a hydrophobic PPO 
core and a hydrophilic PEO shell.  
Furthermore, in the search for new materials that self-assemble in water to form 
nanocarriers, hybrid linear-dendritic block copolymers have been proposed in the last 
years[12]. These structures are formed by the combination of linear chains of a 
polymer and dendritic segments in the chain’s end. Dendritic structures are highly 
branched macromolecules composed of three parts: the core, the branching units that 
give rise to the different generations, and the periphery, which allows the introduction 
of a wide variety of functional groups. The number of functional groups in the periphery 
is determined by the generation. Dendrimers based on 2,2-bis(hydroxymethyl)propionic 
acid (bis-MPA) present several features that make them ideal candidates for their use in 
biomedical applications, i.e. their in vivo and in vitro biocompatibility, their solubility in 
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biological environments and their ability to degrade through a hydrolytic process of the 
ester bonds[13]. 
Joining these trends and requirements, the Liquid Crystals and Polymers research group 
initiated a new working approach focused on CLPMs from thermoresponsive linear-
dendritic block copolymers based on Pluronic® F127 to be used as drug delivery 
nanocarriers[14],[15], with encouraging results opening new design possibilities which 
inspire the current research master project. 
 
2. OBJECTIVES AND WORKING PLAN 
The aims of this research work are the design and synthesis of new amphiphilic block 
copolymers with the ability to self-arrange in water forming micelles, which will be 
photopolymerized in order to obtain cross-linked polymeric micelles, with 
applications as nanocarriers in drug delivery.  
The motivations and plan followed in the realization of this work consists of the steps 
outlined below: 
1) Design, synthesis and characterization of the Pluronic® F127 derivatives: 
Starting from the commercial block copolymer Pluronic® F127, two different 
derivatives will be synthesized (Scheme 1). The first one will be a linear block 
copolymer derivative, F127-A-2, whereas the second compound will be a hybrid 
dendritic-linear-dendritic block copolymer, F127-A-4. They both incorporate 
carbamate moieties within their structure with the aim of promoting hydrogen bonding 
interactions, which could affect both the micellization process and the interaction with 
the encapsulated molecules, thereby increasing the load capacity of the corresponding 
CLPMs. In the case of the hybrid dendritic-linear-dendritic derivative, a first generation 
dendron of bis-MPA will be incorporated, in order to increase the number of functional 
groups in the polymer periphery. Finally, both Pluronic® F127 derivatives will be 
functionalized with acrylate groups, allowing their crosslinking by means of 
photopolymerization. The linear compound will present two acrylate groups in the 
chain’s end, whereas the hybrid dendritic-linear-dendritic one has four 
photopolymerizable groups in the periphery. 
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Scheme 1. Chemical structure of synthesized Pluronic® F127 derivatives. 
The two synthesized compounds, as well as the intermediates of their preparation, will 
be chemically characterized by conventional characterization techniques, i.e. 1H-NMR, 
13C-NMR and FT-IR. 
2) Preparation of CLPMs in water 
CLPMs will be obtained by means of the photopolymerization of micellar aggregates of 
the Pluronic® F127 derivatives formed in water. To achieve this objective, the Critical 
Micelle Concentration (CMC) will be first determined for both derivatives in order to 
know the exact concentration above which the block copolymers started to self-
assemble. Then, polymer solutions of concentrations above the CMC will be prepared, 
and the structure of the preformed micelle aggregates will be fixed through 
photocrosslinking in presence of a commercial photoinitiator.  
Photocrosslinking at different concentrations of the block copolymers will be carried 
out in order to determine its influence in the final shape and size of the CLPMs. 
3) Morphological characterization of CLPMs 
CLPMs morphology will be studied by different characterization techniques suitable for 
nanometric materials, i.e. DLS, TEM and SEM. Moreover, since CLPMs are 
composed by thermosensitive materials, the temperature influence in size will be also 
studied. 
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4) Drug encapsulation 
Finally, CLPMs will be tested for their application as nanocarriers. Two different drugs, 
a liposoluble (camptothecin) and a hydrosoluble one (chloroquine), will be 
encapsulated. For this purpose, two different encapsulation techniques will be 
employed.  
 
3. RESULTS AND DISCUSSION 
3.1. Synthesis and characterization of Pluronic® F127 derivatives 
3.1.1. Synthesis and characterization of the linear Pluronic® F127 derivative, F127-A-2. 
The synthetic route followed to obtain F127-A-2 consists of several steps detailed in 
Scheme 2.  
Firstly, commercial Pluronic© F-127 was made to react with p-nitrophenyl 
chloroformate, giving rise to F127-NP-2. The p-nitro phenyloxy group of the obtained 
carbonate functionality acted as a good leaving group, and in presence of ethanolamine 
reacted with its amino group to form a carbamate, resulting in F127-C-2. Finally, 
acrylate groups were introduced by means of the reaction of the hydroxyl groups in 
F127-C-2 with acryloyl chloride. In the first attempts, the full functionalization of 
F127-C-2 with acrylate groups was not achieved.  
In order to completely incorporate the acrylate groups, different reaction conditions 
were checked. The presence of a little amount of water entrapped within the polymer 
and in the reaction solvent was proved to be one of the problems that caused the 
incomplete functionalization, since it quickly reacts with acryloyl chloride to give rise 
to the non-reactive carboxylic acid. Therefore, first, freshly distilled dichloromethane 
was used as the reaction solvent, and F127-C-2 was thoroughly dried under vacuum and 
above its boiling point. Secondly, the concentration of reactants was also a key point. 
Finally, the complete functionalization was achieved for dry conditions and using the 
smallest amount of solvent to solubilize the reagents during the reaction. 
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Scheme 2. Synthetic route to obtain F127-A-2. 
The correct functionalization of Pluronic© F-127 in each step of the synthetic route was 
corroborated by NMR and FT-IR.  
Pluronic© F-127 present two characteristic signals in the 1H-NMR spectrum. The first 
one appears at 1.12 ppm and integrates for 201 H corresponding to the methyl groups in 
the PPO block. The second one emerges as a complex signal from 3.30 to 3.70 ppm and 
integrates for about 1100 H, corresponding to the hydrogen atoms corresponding to the 
H-C-O systems in both PPO and PEO blocks. When Pluronic© F-127 is functionalized, 
the presence of new signals, and specially their relative integration in comparison with 
the Pluronic signals, provides useful information to discern whether the 
functionalization was successfully achieved or not. 
In the case of F127-NP-2 (Figure 1), three new signals appear in the 1H-NMR spectrum 
with respect to Pluronic© F-127. A multiplet integrating for 4 H at 4.41 ppm, which 
corresponds to PPO block protons directly linked to the carbonate group, is observed, 
since these hydrogen atoms are no more similar to those of the rest of the PPO chain. In 
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addition, two signals, integrating for 4 H each one, appear at 7.39 ppm and 8.27 ppm. 
These signals correspond to the hydrogen atoms of the aromatic ring.  
The correct synthesis of F127-C-2 can be checked by the displacement of the multiplet 
from 4.41 ppm to 4.21 ppm (Figure 1), due to the transformation of the carbonate group 
to a carbamate one, as well as by the disappearance of the two signals at 7.39 ppm and 
8.27 ppm corresponding to the aromatic protons. In addition, a broad signal appears at 
5.51 ppm. This signal corresponds to the N-H protons of the carbamate group.  
Finally, the 1H-NMR spectrum of F127-A-2 (Figure 1) shows three new doublets of 
doublets integrating for 2 H each one between 5.84 ppm and 6.44 ppm. These signals 
are characteristic of acrylate groups, and their correct integration confirms the complete 
functionalization.  
Pluronic© F-127 derivatives were also characterized by means of 13C-RMN. However, 
some of the characteristic peaks corresponding to the functionalization of the ends of 
the chain were difficult to observe. Specially, the signal corresponding to the carbonyl 
carbon atoms was very weak and difficult to assign. 
 
Figure 1. 1H-NMR spectra of F127-NP-2, F127-C-2 and F127-A-2 in CDCl3 (400 MHz).The 
assignment of each signal is detailed in the Annexes. 
F127-A-2
F127-C-2
F127-NP-2
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In addition to NMR, FT-IR has been used to follow the reactions. The FT-IR spectra of 
F127-NP-2, F127-C-2 and F127-A-2 are shown in Figure 2. The peak corresponding to 
the stretching vibration of the C=O bond provides useful information to determine if the 
carbonate group of F127-NP-2 has been replaced by a carbamate group in F127-C-2 
and F127-A-2. In F127-NP-2, this peak appears at 1765 cm-1, whereas in F127-C-2 and 
F127-A-2, the peaks are shifted to lower wavenumbers: 1722 cm-1 and 1728 cm-1 
respectively. Moreover, the presence of hydroxyl groups at both ends of the chain can 
also be observed in the FT-IR spectrum. Pluronic© F-127 and F127-C-2 present 
hydroxyl-terminated chains. Thus, a wide signal is observed from 3500 to 3200 cm-1. 
These signals, which correspond to the stretching of the O-H bond in hydroxyl groups, 
are not observed in the spectra of F127-NP-2 and F127-A-2.  
 
Figure 2. IR spectra of F127-NP-2, F127-C-2 and F127-A-2 (neat on NaCl). Presence and 
absence of the O-H stretching band and displacement of the stretching C=O vibration for each 
compound. 
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3.1.2. Synthesis and characterization of the hybrid dendritic-linear-dendritic Pluronic® 
F127 derivative, F127-A-4. 
The synthetic route followed to obtain F127-A-4 consists of several steps detailed in 
Scheme 3. 
 
Scheme 3. Synthetic route to obtain F127-A-4. 
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Starting from commercial Pluronic© F-127, the reaction with benzylidene-2,2-
bis(oxymethyl) propionic anhydride gave rise to F127-Bn-2[16]. This anhydride was 
previously synthesized from commercial 2,2-bis(hydroxymethyl) propionic acid, which 
was first made react with benzaldehyde dimethyl acetal to protect the hydroxyl groups 
and subsequently condensed to obtain the respective anhydride. The hydroxyl groups of 
F127-Bn-2 were deprotected by means of hydrogenation with H2 catalyzed by Pd/C to 
obtain F127-OH-4.  
The incorporation of the bis-MPA dendritic structure at the end of the polymeric chains 
increased the number of terminal hydroxyl groups from two to four. Then, the same 
synthetic route as in the case of the linear derivative was followed: the reaction of F127-
OH-4 with p-nitrophenyl chloroformate gave rise to F127-NP-4. The carbamate group 
of F127-C-4 was obtained through reaction of F127-NP-4 with ethanolamine. In both 
reactions, the conditions were adjusted in order to incorporate the four functional 
groups. Finally, the introduction of acrylate groups was attempted.  
Unlike in the case of the linear derivative, the complete functionalization was not 
achieved for the hybrid dendritic-linear-dendritic Pluronic© F-127 derivative. The 
reaction conditions optimized for the linear derivative were applied to obtain F127-A-4. 
In addition, both trimethylamine and acryloyl chloride, the reactants used during the 
acrylation process, were distilled too. Moreover, the reaction time was increased up to 
three days. Nevertheless, only partial acrylation was accomplished, even under dry 
conditions, at high reactant concentrations and long reaction times. The number of 
acrylate groups introduced during the reaction was not reproducible. At best, a 
functionalization of the 60 % was achieved, as determined by the integration of the 
characteristic signals of acrylate groups in the 1H-NMR spectrum (see Annexes). As a 
consequence of these results, only F127-A-2 has been used for posterior studies of this 
master project. 
The characterization of all the compounds obtained during the synthetic process was 
similar to that of the linear derivative. 1H-NMR and FT-IR were used to confirm the 
presence of the functional groups in each step of the synthesis (see Annexes).  
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3.2. Preparation of CLPMs 
3.2.1. Critical Micelle Concentration determination. 
The Critical Micelle Concentration is a characteristic value of amphiphilic materials that 
defines the concentration above which they start to self-assemble forming micelles in a 
solvent. When F127-A-2 is placed in water, the lipophilic chains interact with 
themselves to form the core and the hydrophilic parts are extended towards the aqueous 
solution. The lipophilic core is formed by the PPO block, whereas the hydrophilic 
chains are the PEO blocks. The determination of the CMC in water was required since 
the posterior photopolymerization process were performed at concentrations above this 
value, ensuring the formation of the aggregates. 
For the determination of the CMC in water, the pyrene method[17] was carried out. This 
method is based on the difference in the excitation spectrum of pyrene depending on 
whether it is in a hydrophilic environment (λexc máx=332 nm) or in a lipophilic 
environment (λexc máx=335 nm). Therefore, in copolymer water solutions below the 
CMC, pyrene will be in a hydrophilic environment, whereas for copolymer 
concentrations above the CMC, pyrene, which is a lipophilic molecule, will be 
encapsulated within the lipophilic core of the self-assembled micelles. Accordingly, the 
encapsulation of pyrene shifts its excitation maximum from 332 nm to 335 nm. 
Representing the intensities ratio -I335/I332- versus the polymer concentration logarithm 
(logC), the CMC can be determined by calculating the intersection between the two 
linear domains of the graph (Figure 3). 
 
Figure 3. Plot of the excitation maxima intensities ratio of pyerene vs F127-A-2 concentration 
for CMC calculation. 
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To obtain this graph, solutions of F127-A-2 of concentrations 0.0001, 0.001, 0.01, 0.05, 
0.1, 0.3, 0.5 and 1 % (w/v) were prepared (1 % (w/v) is equal to 10 mg/mL). A pyrene 
solution was added to obtain a final pyrene concentration of 6·10-8 M, and the excitation 
spectra from 300 to 350 nm and λem=390 nm was recorded. Temperature strongly 
affects the CMC value, so the sample’s preparation and the measurements were carried 
out at 25⁰C. 
The CMC for F127-A-2 was 0.025 % (w/v). This value is much lower than that of 
Pluronic© F-127, which has a CMC of 0.25 % (w/v). The decrease in one order of 
magnitude of the CMC value for F127-A-2 with respect to commercial Pluronic may be 
due to the effect of the presence of carbamate groups in the chain’s end that favors the 
formation of hydrogen bonding interactions. These interactions can make the micelles 
more stable, decreasing the minimum concentration above which the block copolymer 
starts to self-aggregate. 
3.2.2. Photopolymerization of self-assembled micelles. 
CLPMs were prepared by means of UV photopolymerization of the reactive acrylate 
groups in distilled water solution containing the block copolymer F127-A-2 and the 
commercial photoinitiator Irgacure 2959. After polymerization, these micelles in 
solution provided crosslinked nanoparticles that contain lipophilic and hydrophilic 
domains. 
In order to study the relationship between the copolymer concentration on the size and 
on the load capacity of the obtained crosslinked nanoparticles, solutions of 1.4% (w/v), 
0.77% (w/v) and 0.50% (w/v) of the copolymer were used to perform the 
photopolymerization process. All these concentrations are above the CMC, so that they 
ensure the self-assembly forming micelles that are necessary for the subsequent 
formation of the crosslinked nanoparticles. Hereinafter, photopolymerized CLPMs at 
the different concentrations will be named as F127-A-2-05, F127-A-2-077 and F127-A-
2-140. 
The photopolymerization process was performed by irradiating the corresponding 
solution with UV light (λ=365 nm) at 25⁰C (The photopolymerization system is 
depicted in the Annexes). Then, the solutions were dialyzed (MWCO 300,000 
membrane) at 4⁰C in order to disaggregate the non-photopolymerized micelles and 
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remove them as the free monomer. In addition, aggregates of sizes smaller than 30 nm 
were removed too. Finally, the solutions were filtered through a 0.2 µm filter to 
eliminate the aggregates of sizes bigger than 200 nm. 
After the photopolymerization, the yield of the process, as well as the final 
concentration of F127-A-2-05, F127-A-2-077 and F127-A-2-140 samples were 
determined by lyophilizing a small aliquot. The yield of the photopolymerization was 
33.7%, 34.5% and 32.7% respectively. The final concentration was 1.87 mg/mL, 2.33 
mg/mL and 4.20 mg/mL, respectively. 
 
3.3. Morphological characterization of the CLPMs 
3.3.1. Dynamic Light Scattering. 
In order to determine the particle size of the CLPMs, DLS experiments were performed. 
These measurements were made at two temperatures in order to observe whether F127-
A-2-077 and F127-A-2-140 presented thermoresponsive properties. The experimental 
data is detailed in Table 1. 
Table 1. Average size and size range of F127-A-2 photopolymerized at different concentrations. 
Sample Average Size (nm) 
(25°C) 
Size Range (nm) 
(25°C) 
Average Size (nm) 
(37°C) 
Size Range (nm) 
(37°C) 
F127-A-2-05 328.7 24.3-712.4 277.5 18.17-615.1 
F127-A-2-077 128.5 24.4-255.0 105.0 21.04-220.2 
F127-A-2-140 160.1 37.8-295.3 149.0 18.17-255.0 
 
Regarding the results, several conclusions can be drawn. Firstly, micelles from the 
lowest concentration, F127-A-2-05, presented a much larger average size than F127-A-
2-077 and F127-A-2-140, and, surprisingly, also particles of sizes up to 700 nm. In fact, 
these sizes do not correspond to those expected for this sample because they were 
filtered through a 0,2 µm filter before the characterization by DLS. Thus, particles 
higher than 200 nm should not be observed. The explanation to this phenomenon may 
be that F127-A-2-05 samples did not form highly crosslinked aggregates, due to the low 
concentration of the reactive polymer. Therefore, aggregates were present in a dynamic 
equilibrium, so that the particles can be disaggregated to pass through the filter and then 
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form again the bigger aggregates observed by DLS. On the other hand, F127-A-2-077 
(128 nm) and F127-A-2-140 (160 nm) do not present that high particle sizes, 
confirming that the photopolymerization process was successfully accomplished and 
bigger aggregates were removed by means of filtration through the 0.2 µm filter. 
Accordingly, only F127-A-2-077 and F127-A-2-140 samples were used for further 
studies. 
Secondly, an increase of the average size was observed when increasing the 
concentration of the polymer during the photopolymerization process from 0.77 % 
(w/v) to 1.40 % (w/v). 
In addition, both types of CLPMs presented a contraction of their volume when the 
temperature was increased to 37°C for F127-A-2-077 (105 nm) and F127-A-2-140 (149 
nm). The size decrease was higher for F127-A-2-12-077 than for F127-A-2-140. One 
reason for this effect may be that the higher amount of polymer in F127-A-2-140 favors 
more compact structures during photopolymerization, and the obtained CLPMs are less 
susceptible of undergoing shrinkage when increasing the temperature. 
3.3.2. Scanning Electron Microscopy and Transmission Electron Microscopy 
In order to analyze the morphology and size of F127-A-2-077 and F127-A-2-140 
CLPMs, SEM and TEM experiments were carried out.  
In both cases, SEM images (Figures 4a and 4b) showed spherical and ovoid 
nanoparticles ranging from 35 to 130 nm. Particles of every size within this range were 
observed, although 70 to 110 nm were the predominant sizes. This wide size 
distribution corresponds to that observed in DLS experiments. The smaller sizes 
observed by this technique in comparison with those obtained by DLS can be explained 
because in the latter, the device detects the hydrodynamic radius of the particles, which 
includes the molecules of water surrounding the polymeric aggregate. In addition, the 
intensity method magnifies the signal corresponding to the biggest particles, and this 
effect may distort the average size of the population. Besides, SEM images were 
acquired under high vacuum conditions, and during the evacuation of the SEM chamber 
water molecules entrapped within the hydrophilic shell of the CLPMs were evaporated, 
causing a contraction that may decrease the observed size of the nanoparticles. 
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Figure 4a. SEM image of F127-A-2-12-077 
CLPMs. 
Figure 4b. SEM image of F127-A-2-140 CLPMs. 
 
TEM images (Figures 5a and 5b) showed spherical nanoparticles ranging from 22 to 
150 nm for F127-A-2-077 and from 26 to 141 nm for F127-A-2-140. These results are 
very similar to those observed in SEM experiments. Sizes observed by TEM were also 
smaller than DLS sizes, since this type of experiments are carried out at ultra-high 
vacuum too, evaporating the water surrounding the polymeric nanoparticles and 
producing the contraction of the hydrophilic shell before the acquisition of the images.  
  
Figure 5a. TEM image of F127-A-2-077 CLPMs. Figure 5b. TEM image of F127-A-2-140 CLPMs. 
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3.4. Drug encapsulation experiments 
In order to study the properties of the CLPMs as nanocarriers for drug delivery 
applications, two different compounds were encapsulated: Camptothecin (CPT), a 
liposoluble drug, and Chloroquine (CQ), a hydrosoluble one. The chemical structure of 
both drugs is depicted in Figures 6a and 6b. 
 
 
Figure 6a. Chemical structure of CPT. Figure 6b. Chemical structure of CQ. 
 
3.4.1. Encapsulation of Camptothecin. 
Camptothecin is a poorly water-soluble drug that exhibits remarkable activity against 
different types of cancer[18]. In addition, it has been recently described as a potent 
antiviral agent for HCV[19]. However, CPT presents some drawbacks that limit its 
application in medicine, i.e. very low water solubility and chemical instability due to 
hydrolysis of its lactone ring under physiological conditions. 
F127-A-2-077 and F127-A-2-140 CLPMs were tested as nanocarriers for the 
encapsulation of CPT. The solvent diffusion method[20] was used in order to 
encapsulate CPT. Commercial CPT was dissolved in DMSO and added to a 1mg/mL 
solution of CLPMs in distilled water. The mixtures were mechanically stirred at room 
temperature to ensure the correct encapsulation of CPT within the CLPMs. Then, the 
mixtures were dialyzed against water in order to remove the DMSO, causing 
precipitation of non-encapsulated CPT. The samples were filtered through a 0.45 µm 
PVDF filter, removing non-encapsulated CPT. Two aliquots were lyophilized, 
redissolved in DMSO and encapsulated CPT was quantified by fluorescence emission 
spectrum (λmax=436 nm in DMSO, λexc=368 nm). The fluorescence calibration curve is 
depicted in the Annexes. The load capacities and encapsulation efficiencies are detailed 
in Table 2. As it can be seen, load capacity of F127-A-2-077 and F127-A-2-140 
CLPMs was very similar (around 0.46 µg/mg).  
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Table 2. Camptothecin load capacity and encapsulation efficiency of F127-A-2 CLPMs. 
Sample Load capacity (µg CPT / mg CLPM) Encapsulation efficiency (% w) 
F127-A-2-077 0.475 0.36 
F127-A-2-140 0.444 0.34 
 
Additionally, preliminary studies of drug release for these materials were performed. 
When loaded CLPMs were dialyzed for a week, encapsulated CPT was completely 
released, not observing any emission in the fluorescence spectrum.  
3.4.2. Encapsulation of Chloroquine. 
Chloroquine is a water-soluble drug mainly used to prevent and to treat malaria, as well 
as in cancer therapy[21],[22],[23].  
F127-A-2-077 and F127-A-2-140 CLPMs were tested for the encapsulation of CQ. In 
this case, due to the good solubility of CQ in water, the solvent/oil water emulsion 
method was employed[20]. A 0.75 mg/mL solutions of CLPMs in distilled water were 
extracted with dichloromethane by means of mechanical stirring. Then, commercial CQ 
disphosphate salt in distilled water was added to the CLPMs solution in 
dichloromethane, and the mixture was mechanically stirred until the organic phase was 
completely evaporated, causing the encapsulation. The final concentration of the 
CLMPs and the CQ was 0.50 mg/mL. 
Solutions were dialyzed against distilled water overnight in order to remove the non-
encapsulated CQ. Encapsulated CQ was indirectly quantified by measuring the UV-vis 
absorbance of the dialysis waters. The UV-vis calibration curve is depicted in the 
Annexes. The load capacities and encapsulation efficiencies are detailed in Table 3. 
Table 3. Chloroquine load capacity and encapsulation efficiency of F127-A-2 CLPMs. 
Sample Load capacity (µg CQ / mg CLPM) Encapsulation efficiency (% w) 
F127-A-2-077 135.8 23.9 
F127-A-2-140 293.5 45.4 
 
In addition, the load capacity of F127-A-2-140 CLPMs (293.5 µg/mg) was more than 
two times higher than the load capacity of F127-A-2-077 CLPMs. This significant 
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increase in the load capacity may be produced by the higher size of the F127-A-2-140 
CLPMs, since larger particles will have a larger hydrophilic shell, being able to 
encapsulate more drug amount. 
 
CLPMs of F127-A-2 were proved to have a good load capacity for the encapsulation 
of hydrosoluble compounds, like CQ. On the other hand, liposoluble compounds, e.g. 
CPT, were poorly encapsulated. This effect may be due to the higher availability of 
the hydrophilic shell in comparison with the lipophilic core. Thus, the encapsulation of 
hydrosoluble drugs is easier since they do not have to penetrate to the core.  
Moreover, it is known that Pluronic® F-127 derivatives can form hydrogels at high 
polymer concentrations[24]. Thus, CLPMs could behave as nanostructured hydrogels, i.e. 
nanogels, entrapping a large amount of water within the polymeric network. Since CQ 
is a hydrosoluble compound, the presence of water in the interior of the CLPMs could 
increase the load capacity whereas this effect will not occur for a liposoluble compound 
like CPT. 
 
3.5. In-vitro anti-HCV studies 
In order to study the possibility of the CLPMs to act as nanocarriers for anti-HCV 
drugs, cytotoxicity and anti-HCV effectiveness experiments were carried out with 
camptothecin encapsulated in F127-A-2-077 CLPMs[25]. These experiments were made 
in collaboration with researchers from the Institute for Biocomputation and Physics of 
Complex Systems (BIFI). 
Cytotoxicity of free CPT, encapsulated CPT and CLPMs was determined by cell 
metabolism assays, adding increasing amounts of free CPT, encapsulated CPT and 
CLPMs to HuH52 cells. 
To determine the anti-HCV effectiveness of encapsulated CPT, HCV replicon inhibition 
was monitored. The HCV replicon incorporated a DNA fragment responsible for 
producing a luciferase protein. Therefore, inhibition of the HCV virus replication can be 
observed by means of the decrease in luminescence of the cell culture. 
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Experimental conditions were conditioned by the low CPT encapsulation level in the 
CLPMs, so that the amount of water solution containing the CLPMs which was added 
to the cell culture was very high, diluting culture medium. As a consequence cells did 
not have a sufficient amount of nourishment, decreasing the cell viability. 
Cytotoxicity of free CPT and encapsulated CPT is detailed in Figure 7 As it can be 
observed, encapsulated CPT presented higher cell viabilities in comparison with free 
CPT at low CPT concentrations, whereas cytotoxicity of both samples was almost the 
same at high CPT concentrations. In addition, CLPMs always presented cell viabilities 
above 80%. 
Anti-HCV effectiveness experiments were also performed. Unfortunately, due to the 
high amount of encapsulated CPT-containing solution that was added to the cell culture, 
these experiments did not offered conclusive results. New experiments have to be 
carried out in order to determine whether encapsulated CPT has anti-viral effects or not. 
 
Figure 7. Cell titter experiment for CPT and F127-A-2-077 CLPMs. 
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4. EXPERIMENTAL SECTION 
4.1. Synthesis of the linear Pluronic derivative 
·Synthesis of F127-NP-2 
 
Pluronic® F127 (5 g, 0.40 mmol, 1.00 eq.) was dried at 100⁰C for 2h and dissolved in 
15 mL of dry dichloromethane. 4-nitrophenyl chloroformate (640 mg, 3.18 mmol, 7.95 
eq.) was dissolved in 5 mL of dry dichloromethane and slowly added. Finally, pyridine 
(0.4 mL, 4.96 mmol, 12.50 eq.) was added dropwise, forming a white precipitate. The 
reaction mixture was stirred at room temperature under Ar atmosphere overnight. The 
crude was dissolved in 100 mL of dichloromethane and it was washed twice with 150 
mL of NaHSO4 1M and with 150 mL of brine. The organic phase was dried over 
MgSO4 and concentrated at reduced pressure. The product was precipitated in 300 mL 
of cold diethyl ether and stored in the refrigerator overnight, filtered and washed with 
cold diethyl ether to obtain a white powder. Yield: 78%. Mass: 3.91 g. 
1H-RMN (400 MHz, CDCl3) δ (ppm): 1.10-1.14 (m, 201 H), 3.33-3.70 (m, ~1100H), 
3.78-3.82 (m, 8H), 4-40-4.44 (m, 4H), 7.38 (d, J=9.2 Hz, 4H), 8.27 (d, J=9.2 Hz, 4H). 
FT-IR (neat on NaCl, cm-1): 2864 (ν C-H), 1770 (ν C=O carbonate), 1454 (δ C-H), 1100 
(ν C-O-C). 
 
·Synthesis of F127-C-2 
 
F127-NP-2 (4.26 g, 0.34 mmol, 1.00 eq.) was dried at 100⁰C for 2h and dissolved in 15 
mL dry dichloromethane. Ethanolamine (80 mg, 1.31 mmol, 3.85 eq.) was solved in 10 
mL and slowly added, turning the solution yellow. The reaction mixture was stirred at 
room temperature under Ar atmosphere overnight. The product is precipitated in 200 
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mL of cold diethyl ether, stored in the refrigerator overnight, filtered and washed with 
cold diethyl ether to obtain a white powder. Yield: 78%. Mass: 3.30 g. 
1H-RMN (400 MHz, CDCl3) δ (ppm): 1.11-1.15 (m, 201 H), 3.30-3.82 (m, ~1100H), 
4.20-4.25 (m, 4H), 5.42-5.60 (bs, 2H). 
FT-IR (neat on NaCl, cm-1): 3670-3250 (ν O-H), 2870 (ν C-H), 1722 (ν C=O), 1454 (δ 
C-H), 1107 (ν C-O-C). 
 
·Synthesis of F127-A-2 
 
F127-C-2 (1g, 0.079 mmol, 1.00 eq.) was dried at 150⁰C with vacuum and dissolved in 
8 mL of dry dichloromethane. 4-methoxyphenol (130 mg) was added. Triethylamine 
(0.115 mL, 0.83 mmol, 10.50 eq.) was slowly added and the reaction mixture was 
cooled down at 0⁰C and protected from light. After 15 minutes, acryloyl chloride (0.06 
mL, 0.74 mmol, 9.40 eq.) was very slowly added, and the reaction mixture was stirred 
under Ar atmosphere for 48h. The crude is passed through a neutral alumina column, it 
was precipitated in 10 mL of cold diethyl ether, stored in the refrigerator overnight, 
filtered and washed with cold diethyl ether to obtain a white powder. Yield: 49%. Mass: 
485 mg. 
1H-RMN (400 MHz, CDCl3) δ (ppm): 1.11-1.14 (m, 201 H), 3.32-3.82 (m, ~1100H), 
4.19-4.25 (m, 8H), 5.12-5.21 (bs, 2H), 5.86 (dd, Jcis=10.4 Hz, Jgem= 1.4 Hz, 2H), 6.11 
(dd, Jtrans=17.2 Hz, Jcis= 10.4 Hz, 2H), 6.42 (dd, Jtrans=17.2 Hz, Jgem= 1.4 Hz, 2H). 
FT-IR (neat on NaCl, cm-1): 2882 (ν C-H), 1722 (ν C=O), 1467 (δ C-H), 1107 (ν C-O-
C). 
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4.2. Synthesis of the hybrid dendritic-linear-dendritic Pluronic derivative 
·Synthesis of Benzylidene-2,2-bis(oxymethyl)propionic acid 
 
2,2-Bis(hydroxymethyl)-propionic acid (20 g, 149 mmol, 1.00 eq.), benzaldehyde 
dimethyl acetal (33.6 mL, 224 mmol, 1.50 eq.) and p-toluenesulfonic acid monohydrate 
(1.42 g, 7.45 mmol, 0.05 eq.) were dissolved in 150 mL of dry acetone. The reaction 
mixture was stirred at room temperature under Ar atmosphere for 4h and then it was 
stored in the refrigerator overnight. The precipitate was filtered and washed with cold 
acetone to obtain a white powder. Yield: 59%. Mass: 19.55 g. 
1H-RMN (400 MHz, CDCl3) δ (ppm): 1.11 (s, 3H), 3.70 (d, J=11.6 Hz, 2H), 4.64 (d, 
J=11.6 Hz, 2H), 5.49 (s, 1H), 7.33-7.38 (m, 3H), 7.45-7.50 (m, 2H). 
13C-RMN (100 MHz, CDCl3): δ (ppm): 17.7, 42.2, 73.4, 101.9, 126.1, 128.3, 129.1, 
137.5, 178.8. 
FT-IR (ATR, cm-1): 3005 (ν OH), 2875 (ν C-H), 1696 (ν C=O). 
 
·Synthesis of Benzylidene-2,2-bis(oxymethyl)propionic anhydride 
 
Benzylidene-2,2-bis(oxymethyl)propionic acid (6 g, 27 mmol, 1.00 eq.) was dissolved 
in 80 mL of dry dichloromethane. N,N´-Dicyclohexylcarbodiimide (3.06 g, 14.85 
mmol, 0.55 eq.) dissolved in 10 mL of dry dichloromethane was slowly added. The 
reaction mixture was stirred at room temperature under Ar atmosphere overnight. A 
white precipitate appeared and it was filtered off and washed with a small amount of 
dichloromethane. The organic phase was concentrated at reduced pressure and the 
product was precipitated into 700 mL of cold hexane. The precipitate was stored at the 
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refrigerator overnight and it was filtered and washed with cold hexane to obtain a white 
powder. Yield: 95%. 
1H-RMN (400 MHz, CDCl3) δ (ppm): 1.12 (s, 6H), 3.69 (d, J=11.6 Hz, 4H), 4.66 (d, 
J=11.6 Hz, 4H), 5.47 (s, 2H), 7.31-7.35 (m, 6H), 7.43-7.48 (m, 4H). 
13C-RMN (100 MHz, CDCl3): δ (ppm): 16.8, 44.2, 73.2, 102.1, 126.3, 128.2, 129.3, 
137.6, 169.1. 
FT-IR (ATR, cm-1): 2875 (ν C-H), 1816 (ν C=O symmetric), 1746 (ν C=O asymmetric). 
 
·Synthesis of F127-Bn-2 
 
Pluronic® F127 (10 g, 0.79 mmol, 1.00 eq.) was dried at 100⁰C for 2h and dissolved in 
20 mL of dry dichloromethane. 4-Dimethylaminopyridine (320 mg, 2.54 mmol, 3.22 
eq.) and 2,2-bis(oxymethyl)propionic anhydride (2.71 g, 6.35 mmol, 8.00 eq.) were 
added and the reaction mixture was stirred at room temperature under Ar atmosphere 
overnight. 4 mL of methanol were added and the reaction mixture was stirred for 6h in 
order to quench the reaction. Then, it was precipitated in 1 L of cold diethyl ether and 
stored in the refrigerator overnight, filtered and washed with cold diethyl ether to obtain 
a white powder. Yield: 92%. Mass: 9.45 g.  
1H-RMN (400 MHz, CDCl3) δ (ppm): 1.03 (s, 6H), 1.10-1.14 (m, 201H), 3.37-3.80 (m, 
~1100H), 4.34 (t, J=6.0 Hz, 4H), 4.66 (d, J=11.6 Hz, 4H), 5.43 (s, 2H), 7.29-7.33 (m, 
6H), 7.39-7.44 (m, 4H). 
FT-IR (neat on NaCl, cm-1): 2882 (ν C-H), 1742 (ν C=O, ester), 1107 (ν O-C-O).  
 
 
 
 
 
 
24 
 
·Synthesis of F127-OH-4 
 
F127-Bn-2 (6 g, 0.48 mmol, 1.00 eq.) was dried at 100⁰C for 2h and dissolved in 150 
mL of ethyl acetate and three vacuum-argon cycles were made. Pd/C (300 mg, 10% 
(w/w)) was added and another three vacuum-argon cycles were made. Finally, three 
vacuum-hydrogen cycles were made and the reaction mixture was stirred at room 
temperature under hydrogen atmosphere overnight. Pd/C was filtered with Celite® and 
the filtrate was evaporated to obtain a white powder. Yield: 95%. Mass: 5.68 mg. 
1H-RMN (400 MHz, CDCl3) δ (ppm): 1.11 (s, 6H), 1.11-1.15 (m, 201 H), 3.34-3.75 (m, 
~1100H), 4.31-4.34 (m, 4H). 
FT-IR (neat on NaCl, cm-1): 3750-3400 (ν O-H), 2877 (ν C-H), 1739 (ν C=O), 1466 (δ 
C-H), 1107 (ν C-O-C). 
 
·Synthesis of F127-NP-4 
 
F127-OH-4 (2.3 g, 0.18 mmol, 1.00 eq.) was dried at 100⁰C for 2h and dissolved in 20 
mL of dry dichloromethane. 4-nitrophenyl chloroformate (600 mg, 2.98 mmol, 16.2 eq.)  
was dissolved in 5 mL of dry dichloromethane and slowly added. Finally, pyridine 
(0.805 mL, 9.98 mmol, 32.81 eq.) was added dropwise, forming a white precipitate. The 
reaction mixture was stirred at room temperature under Ar atmosphere overnight. The 
crude was dissolved in 40 mL of dichloromethane and it was washed twice with 30 mL 
of NaHSO4 1M and with 30 mL of brine. The organic phase was dried over MgSO4 and 
concentrated at reduced pressure. The product was precipitated in 300 mL of cold 
diethyl ether and stored in the refrigerator overnight, filtered and washed with cold 
diethyl ether to obtain a white powder. Yield: 78%. Mass: 1.80 g. 
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1H-RMN (400 MHz, CDCl3) δ (ppm): 1.06-1.21 (m, 201H), 1.38 (s, 6H), 3.32-3.80 (m, 
~1100H), 4.34 (t, J=4.4 Hz, 4H), 4.46 (d, J=10.8 Hz, 4H), 4.57 (d, J=11.2 Hz, 4H), 7.36 
(d, J=9.2 Hz, 8H), 8.25 (d, J=8.8 Hz, 8H). 
FT-IR (neat on NaCl, cm-1): 2881 (ν C-H), 1770 (ν C=O carbonate), 1465 (δ C-H). 
 
·Synthesis of F127-C-4 
 
F127-NP-4 (1.75g, 0.13 mmol, 1.00 eq.) was dried at 100⁰C for 2h and dissolved in 12 
mL dry dichloromethane. Ethanolamine (47 mg, 0.77 mmol, 5.92 eq.) was solved in 3 
mL of dry dichlorometane and slowly added, turning the solution yellow. The reaction 
mixture was stirred at room temperature under Ar atmosphere overnight. The product 
was precipitated in 150 mL of cold diethyl ether, stored in the refrigerator overnight, 
filtered and washed with cold diethyl ether to obtain a white powder. Yield: 72%. Mass: 
1.26 g. 
1H-RMN (400 MHz, CDCl3) δ (ppm): 1.06-1.17 (m, 201H), 1.22 (s, 6H), 3.24-3.31 (m, 
8H), 3.36-3.81 (m, ~1100H), 4.16-4.31 (m, 12H), 5.62-5.77 (bs, 4H) 
FT-IR (neat on NaCl, cm-1): 3594-3220 (ν O-H), 2874 (ν C-H), 1726 (ν C=O), 1465 (δ 
C-H). 
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·Synthesis of F127-A-4 
 
F127-C-4 (1.20 g, 0.091 mmol, 1.00 eq.) was dried at 160⁰C with vacuum and 
dissolved in 10 mL of dry dichloromethane. 4-methoxyphenol (250 mg) was added. 
Triethylamine (0.162 g, 1.60 mmol, 17.60 eq.) was slowly added and the reaction 
mixture was cooled down at 0⁰C and protected from light. After 15 minutes, acryloyl 
chloride (0.132 g, 1.46 mmol, 16.00eq.) was very slowly added, and the reaction 
mixture was stirred under Ar atmosphere for 48h. The crude is passed through a neutral 
alumina column, it was precipitated in 10 mL of cold diethyl ether, stored in the 
refrigerator overnight, filtered and washed with cold diethyl ether to obtain a white 
powder.  
The 1H-NMR spectrum of the partially functionalized compound is depicted in the 
Annexes. 
 
4.3. Critical Micelle Concentration determination 
Solutions of 1.00% (w/v), 0.50% (w/v), 0.30% (w/v), 0.10% (w/v), 0.05% (w/v), 0.01% 
(w/v), 0.001% (w/v) and 0.0001% (w/v) of the block copolymer in distilled water were 
prepared in order to carry out the CMC determination. Solutions from 1% (w/v) to 0.1% 
(w/v) were obtained by direct dissolution of the material in distilled water, whereas 
solutions from 0.05% (w/v) to 0.0001% (w/v) were obtained by dilution from solutions 
of higher concentration. All the solutions were kept at 4°C for 4h. 
A 1.2·10-5 M pyrene solution was prepared by dissolving 0.485 mg of pyrene in 200 mL 
of distilled water. Due to the low solubility of pyrene in water, it was previously 
dissolved in 2 mL of acetone and added to 200 mL of distilled water. Finally, acetone 
was removed at reduced pressure for 4 hours. 
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10 µL of the pyrene solution were added to the block copolymer solutions, so that the 
final pyrene concentration within the water solutions was 6·10-8 M. The solutions were 
incubated at 25°C and protected from light for one hour. 
The fluorescence spectra of the solutions were recorded from 300 to 350 nm and 
λemission=390 nm. In order to study the self-aggregation of the materials, intensities at 
λ=332 nm and λ=335 nm for all the solutions were measured. A representation of the 
intensities ratio versus the block copolymer concentration was depicted to determine the 
CMC. 
 
4.4. Photopolymerization of self-assembled micelles 
A 10% (w/v) solution of the block copolymer was prepared by dissolving the solid 
block copolymer in distilled water containing 0.10% (w/v) of the commercial 
photoinitiator Irgacure 2959. This solution was kept overnight at 4⁰C in order to ensure 
a complete and homogeneous dissolution of the material. 
The solution was filtered through a 0.2 µm filter of cellulose acetate to remove 
suspended particles. 
From this 10% (w/v) solution, solutions of 1.4% (w/v), 0.77% (w/v) and 0.50% (w/v) 
were prepared by diluting with an aqueous solution containing 0.1% (w/v) of Irgacure 
2959 previously filtered. 
These solutions were kept at room temperature for 1h to reach the equilibrium. 
5 mL of these block copolymer solutions were placed in a cylindrical 5 cm diameter 
glass vessel and photopolymerized by irradiating with UV light (λ=365 nm) for 10 
minutes with 8 cm distance between the glass vessel and the lamp. The 
photopolymerization was carried out at 25⁰C. The temperature was controlled by means 
of a hotplate, on which the glass vessel was placed. 
The photopolymerized solutions were dialyzed against distilled water at 4⁰C for 24h 
using a cellulose acetate membrane Spectra/Por® Biotech MWCO 300,000 (Spectrum) 
with a pore size of 30 nm. The dialysis was carried out to purify the CLPM by removing 
the unreacted remaining molecules of the block copolymer.  
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Finally, the dialyzed solutions were filtered again with a 0.2 µm cellulose acetate filter 
to remove aggregates of sizes bigger than 200 nm. 
 
4.5. Encapsulation of Camptothecin 
1mg/mL CPT solution in DMSO was prepared from commercial solid CPT. 
Solutions of F127-A-2-077 and F127-A-2-140 at 1 mg/mL were prepared by diluting 
the CLPMs solutions obtained after the polymerization process. 
To 2 mL of these solutions, 700 µL of DMSO and 300 µL of CPT 1 mg/mL in DMSO 
were added, so that the final solution presents a VDMSO:VH2O ratio of 0.5 and a 
mCPT:mF127-A-2 ratio of 0.15. Then, these solutions were incubated at room temperature 
for 24 hours. 
DMSO was eliminated by dialysis (Spectra/Por MWCO 2000, Spectrum) for 3 days.  
Dialyzed samples were filtered through 0.45 µm PVDF filters in order to eliminate non-
encapsulated CPT.  
Encapsulated CPT quantification was directly carried out by taking 100 µL the filtered 
solutions, lyophilizing them and re-dissolving them in a known DMSO volume. Then, 
CPT was quantified by fluorescence emission spectrum (λmax=436 nm in DMSO with 
λexc=368 nm) by using a calibration curve in the concentration range from 11.2 to 39.2 
µg/mL in DMSO. 
 
4.6. Encapsulation of Chloroquine 
Solutions of F127-A-2-077 and F127-A-2-140 at 0.75 mg/mL were prepared by 
diluting the CLPMs solutions obtained after the polymerization process. 
1.33 mL of these solutions were added to 2 mL of dichloromethane and the mixture was 
incubated for 15 minutes in order to extract the CLPMs from the aqueous phase and 
dissolve them in the CH2Cl2.  
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A 1.30 mg/mL CQ solution was prepared by dissolving commercial solid chloroquine 
diphosphate in distilled water. 
0.77 mL of the CQ solution were added to the water/CH2Cl2 solution containing the 
CLPMs. Then, in order to remove the CH2Cl2, the new mixtures containing both the 
CLPMs and the drug were mechanically stirred at room temperature until only the 
aqueous phase was observed, so that the final aqueous solution presented a CLPM and 
drug concentration of 0.5 mg/mL. 
These solutions were dialyzed (Slide-A-Lyzes® Dialysis Cassette G2 2000 MWCO, 
Thermo Scientific) for 16 hours in order to remove the non-encapsulated drug. 
Encapsulated CQ quantification was indirectly carried out by taking samples from the 
dialysis waters. Non-encapsulated CQ was determined by measuring the absorbance at 
λ=345 nm and using a calibration curve in the concentration range from 2.5 to 25 
µg/mL in distilled water. Encapsulated CQ was then calculated by subtracting the CQ 
amount present in the dialysis waters to the initial amount of CQ placed in the CLPM 
containing solution. 
 
5. CONCLUSIONS 
The work carried out in this Final Master Project has allowed the following conclusions: 
 The chemical modification of Pluronic® F127 with carbamate-based 
moieties to introduce terminal photopolymerizable acrylate group has 
enabled the preparation of Cross-Linked Polymeric Micelles, CLPMs. 
 The CLPMs present morphologies and sizes, thermosensitive properties, 
drug load capacities and cell viabilities that make them good candidates 
for their application as nanocarriers in drug delivery. 
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